戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 f benzolamide (1-2 microM), an extracellular carbonic anhydrase inhibitor.
2 ng the reluctance toward prescribing an oral carbonic anhydrase inhibitor.
3 e authors have shown this to be the case for carbonic anhydrase inhibitors.
4 ient did not respond to systemic and topical carbonic anhydrase inhibitors.
5 xaborinines hold promise for designing novel carbonic anhydrase inhibitors.
6 inically relevant acid-base transporters and carbonic-anhydrase inhibitors.
7                       Azide derivatives of 2 carbonic anhydrase inhibitors, 4-(2-aminoethyl)benzenesu
8                 Following application of the carbonic anhydrase inhibitor acetazolamide (100 microM)
9 files in vivo revealed that ingestion of the carbonic anhydrase inhibitor acetazolamide and the ion e
10 ich was sensitive to Na(+)withdrawal, to the carbonic anhydrase inhibitor acetazolamide and to H2DIDS
11                                          The carbonic anhydrase inhibitor acetazolamide has been used
12 tment of B. pertussis-infected mice with the carbonic anhydrase inhibitor acetazolamide reduced lung
13 CO3(-) is slowed more than three-fold by the carbonic anhydrase inhibitor acetazolamide.
14            We found that the clinically used carbonic anhydrase inhibitors, acetazolamide, ethoxzolam
15 sant therapy included topical beta blockers, carbonic anhydrase inhibitors, and/or alpha agonists.
16                                              Carbonic anhydrase inhibitors are effective in lowering
17 In this connection, we report a new class of carbonic anhydrase inhibitors, based on the thiopyrano-f
18                                          The carbonic anhydrase inhibitor benzolamide (2 x 10(-5) M),
19 loride but was absent in the presence of the carbonic anhydrase inhibitor benzolamide or when the exo
20 g PT sodium and volume reabsorption with the carbonic anhydrase inhibitor benzolamide: 2 mg/kg in 300
21 the effect of subclasses of medications (eg, carbonic anhydrase inhibitors, beta-blockers, alpha-adre
22 present the design and synthesis of 39 novel carbonic anhydrase inhibitors by a dual-tailed approach,
23  nonsteroidal anti-inflammatory drug (NSAID)-carbonic anhydrase inhibitor (CAI) agents for the manage
24  prostaglandin analogue (PGA), beta-blocker, carbonic anhydrase inhibitor (CAI) and alpha-2 agonist a
25                         MTZ is known to be a carbonic anhydrase inhibitor (CAI); however, CAIs acetaz
26 CT) imaging was performed and treatment with carbonic anhydrase inhibitors (CAI) was provided to redu
27  approach based on the hybridization between carbonic anhydrase inhibitors (CAIs) and CO releasing mo
28  controls), to have a history of taking oral carbonic anhydrase inhibitors (CAIs) at tube opening (21
29 he study was to assess the effect of topical carbonic anhydrase inhibitors (CAIs) on selected oxidati
30 3)-AR) agonist mirabegron, with prototypical Carbonic Anhydrase Inhibitors (CAIs) to afford the carba
31 sts (AAAs), beta-adrenergic blockers (BABs), carbonic anhydrase inhibitors (CAIs), ROCKIs, and their
32 ta blockers (BBs), alpha agonists (AAs), and carbonic anhydrase inhibitors (CAIs).
33 ta-blockers [BBs], alpha agonists [AAs], and carbonic anhydrase inhibitors [CAIs]).
34                Given methazolamide, a potent carbonic anhydrase inhibitor, can penetrate the blood-br
35 ic antidepressants, atypical antipsychotics, carbonic anhydrase inhibitors, corticosteroids, 5alpha-r
36 ation, use of topical beta blockers, topical carbonic anhydrase inhibitors, daily dose of BAK, and gl
37    After pretreatment of the tongue with the carbonic anhydrase inhibitor dorzolamide, neuronal respo
38 atched patients initiated an oral or topical carbonic anhydrase inhibitor during the 25-year study pe
39 d that inhibition of the CupB protein by the carbonic anhydrase inhibitor ethoxzolamide (EZ) suppress
40 ave demonstrated that the FDA-approved human carbonic anhydrase inhibitor ethoxzolamide potently inhi
41 mologists may be reluctant to prescribe oral carbonic anhydrase inhibitors, given the potential for l
42                         The oral and topical carbonic anhydrase inhibitor groups had similar baseline
43 ients, whereas patients prescribed a topical carbonic anhydrase inhibitor had an absolute risk of 2.0
44                  Patients prescribed an oral carbonic anhydrase inhibitor had an absolute risk of a s
45                 Treatment of MG with an oral carbonic anhydrase inhibitor hastened anatomic recovery
46                                 Although the carbonic anhydrase inhibitors have been used in the trea
47 il approach" has become a milestone in human carbonic anhydrase inhibitor (hCAI) design for various t
48  chronically treated with bicarbonate or the carbonic anhydrase inhibitor hydrochlorothiazide had par
49 ves were successfully translated into potent carbonic anhydrase inhibitors (IC(50) = 20.1-68.7 nM), w
50 difluprednate with the addition of a topical carbonic anhydrase inhibitor in 6 eyes and nonsteroidal
51 years who were prescribed an oral or topical carbonic anhydrase inhibitor in Ontario, Canada, between
52  macular edema (CME), and review the role of carbonic anhydrase inhibitors in management.
53 f dichlorphenamide (DCP; Daranide), a potent carbonic anhydrase inhibitor, in the treatment of episod
54 e of topical benzalkonium chloride-preserved carbonic anhydrase inhibitors increases oxidative stress
55                     Ethoxyzolamide, a potent carbonic anhydrase inhibitor, inhibits bicarbonate-media
56 ng of pICA, the previously identified 79-kDa carbonic anhydrase inhibitor isolated from porcine plasm
57                    Prostaglandin analogs and carbonic anhydrase inhibitors lower both diurnal and noc
58                                              Carbonic anhydrase inhibitors may be effective in promot
59           Nd:YAG laser hyaloidotomy and oral carbonic anhydrase inhibitors may lead to greater IOP re
60                                              Carbonic anhydrase inhibitors may promote resolution of
61 my may impede time to recovery from MG, oral carbonic anhydrase inhibitors may shorten the time to an
62 n the absence of HCO3- by treatment with the carbonic anhydrase inhibitor methazolamide.
63 Finally, we found that a clinically approved carbonic anhydrase inhibitor, methazolamide, reduced pla
64 on was greater in subjects treated with oral carbonic anhydrase inhibitors (P = .016) or Nd:YAG laser
65 icarbonate co-transporter (P </= 0.0001) and carbonic anhydrase inhibitors (P = 0.0021).
66   Other glaucoma medications (beta blockers, carbonic anhydrase inhibitors, parasympathomimetics, and
67 ed the 1,3,4-thiadiazole acetazolamide human carbonic anhydrase inhibitor scaffold can be repositione
68                 The heterocyclic sulfonamide carbonic anhydrase inhibitor (SCAI) 6-ethoxyzolamide (ET
69  receiving eye drops for glaucoma (including carbonic anhydrase inhibitors selected by NHI drug code)
70 s: To explore safety and tolerability of the carbonic anhydrase inhibitor sulthiame (STM) in OSA.
71 ion that was ameliorated by acetazolamide, a carbonic anhydrase inhibitor that minimizes EA1 symptoms
72                     Whether acetazolamide, a carbonic anhydrase inhibitor that reduces proximal tubul
73          Cystoid macular edema refractory to carbonic anhydrase inhibitor therapy and ultimately amen
74 following prescription of an oral or topical carbonic anhydrase inhibitor was low and similar between